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INTRODUCTION
Nodal involvement and tumor size are the most impor-
tant prognostic factors for breast cancer patients at different
risk of disease recurrence and/or death (1). Many clinicopa-
thologic variables other than TNM stage have been identi-
fied to predict the clinical course of the disease. However,
identifying all high-risk patients is still difficult. Beyond
the conventional clinicopathologic variables, therefore, novel
prognostic factors are needed to be explored to predict the
outcome more accurately (2). Molecular markers such as p53
and bcl-2 have been extensively evaluated for their prognos-
tic value since the 1990s (2-5). Although the prognostic value
of p53 and bcl-2 expression in breast cancer has been evalu-
ated in a number of studies, the results were controversial.
Heterogeneous patient and tumor characteristics might be
partly responsible for the discrepancy. Treatments were also
various with mastectomy (6, 7) breast conservative therapy
(8-11) or the combination of the two (12-14).
Given these observations, we evaluated the prognostic val-
ue of p53 and bcl-2 expression on the treatment outcome,
in relatively homogeneous population consisted of early stage
breast cancer patients who underwent breast conservative
treatment. In addition, the correlation between these mark-
ers and triple-negative phenotype was also investigated.
MATERIALS AND METHODS
Between March 2000 and February 2002, 125 patients
underwent radiotherapy after breast conserving surgery for
breast cancer. Of these, 100 patients whose immunohisto-
chemical staining for p53 and bcl-2 was performed at the
time of diagnosis were the cohorts for this retrospective study.
The median age was 44 yr (range; 24-68). Performance
status of the patients was good with ECOG grade of 0 for
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Prognostic Value of p53 and bcl-2 Expression in Patients Treated 
with Breast Conservative Therapy
Prognostic value of p53 and bcl-2 expression on treatment outcome in breast can-
cer patients has been extensively evaluated, but the results were inconclusive. We
evaluated the prognostic significance of these molecular markers in patients treat-
ed with breast conserving surgery and radiotherapy. One hundred patients whose
immunostaining of p53 and bcl-2 expression was available among 125 patients who
underwent radiotherapy after breast conserving surgery and axillary lymph node
dissection were enrolled into this study. Eighty-seven patients also received adju-
vant chemotherapy and/or hormonal therapy. Conventional clinicopathologic vari-
ables and treatment-related factors were also considered. The 5-yr loco-regional
relapse-free and distant metastasis-free survival rates were 91.7% and 90.9%, res-
pectively. On univariate analysis, age, T stage and the absence of bcl-2 & estro-
gen receptor (ER) expression were associated with loco-regional relapse-free sur-
vival. When incorporating these variables into Cox proportional hazard model, only
bcl-2(-)/ER(-) phenotype was an adverse prognostic factor (P=0.018). As for the
distant metastasis-free survival, age, T stage, and p53 expression were significant
on univariate analysis. However, p53 expression was the only prognosticator on
multivariate analysis (P=0.009). A bcl-2(-)/ER(-) phenotype and p53 expression are
useful molecular markers predicting loco-regional relapse-free and distant metas-
tasis-free survival, respectively, in patients treated with breast conserving surgery
and radiotherapy.
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type was invasive ductal carcinoma in 90 patients (90.0%).
All patients had breast conserving surgery with axillary
lymph node dissection. Sixty patients received chemothera-
py: cyclophosphamide, methotrexate and 5-fluorouracil in
30 patients; doxorubicin-containing regimen in 27 patients;
others in 3 patients. Sixty-two patients received hormonal
therapy and 35 of them also received chemotherapy. As re-
gards to radiotherapy, whole breast irradiation was given, up
to 50.4 Gy at 1.8 Gy/fraction by using two opposing tan-
gential photon beams. Tumor bed boost was supplemented
up to 10 Gy at 2 Gy/fraction.
The clinicopathologic findings according to the expression
of p53 and bcl-2 are summarized in Table 1. Median dura-
tion of follow-up was 69 months (range; 21-88).
The specimens were immunostained to determine the ex-
pression of p53, bcl-2 and c-erbB2 as well as the status of es-
trogen receptor (ER) and progesterone receptor (PR). Immu-
nostaining was performed in the usual manner, using anti-
bodies to p53 (Dako, Glostrup, Denmark; 1:1,200), bcl-2
(Dako, 1:50), c-erbB2 (Novacastra Laboratories Ltd., New
Castle upon Tyne, UK, 1:200), ER (Dako, 1:50) and PR
(Dako, 1:50).
The percentage of tumor cells with nuclear staining for
p53 was graded semi-quantitatively: 0%, 1-25%, 26-50%,
51-75% or >75%. For statistical analysis, p53 expression
was considered as negative if ≤25% of tumor cells were
stained and as positive if >25% of tumor cells were stained.
ER/PR and bcl-2 expression were judged as positive when
≥10% of tumor cells were stained in nucleus and membr-
ane, respectively. C-erbB2 expression was considered as pos-
itive if the score was 3, and negative if the score was 0, 1 or 2.
Statistical analysis was done by using SPSS software (release
12.0.1. SPSS Inc., Chicago, IL, USA). Differences in categor-
ical variables between the parameters were compared by us-
ing standard chi-square test or Fisher’s exact test. The actu-
arial survival rates were calculated by using the Kaplan-Meier
method and statistical significance of differences between the
actuarial survival rates was evaluated by the log-rank test.
Cox proportional hazard model was used for multivariate
analysis. For all statistical tests, P values <0.05 were consid-
ered significant.
RESULTS
Patients with p53 expression were more likely to have
node-positive and ER-negative tumors. In contrast, bcl-2
expression was associated with both ER- and PR-positivity.
Expression of p53 was correlated with triple-negative phe-
notype (P=0.011), while bcl-2 negativity was correlated
with triple-negative phenotype (P<0.001). Inverse relation-
ship was demonstrated between p53 and bcl-2 expression
(P=0.004, Table 1).
The 5-yr loco-regional relapse-free and distant metastasis-
free survival rates were 91.7% and 90.9%, respectively. On
univariate analysis, age less than 40 yr and T2 stage were sig-
nificant prognosticators predicting poor loco-regional relapse-
free survival (Table 2). When incorporating these variables
into Cox proportional hazard model, however, both lost the
statistical significance. Given the association between bcl-2
expression and ER status, we tested interaction of the two
variables. Compared with bcl-2(-)/ER(-) phenotype (n=14),
other phenotypes (bcl-2[-]/ER[+], bcl-2[+]/ER[-], and bcl-
2[+]/ER[+]) achieved higher loco-regional relapse-free survival
rate (77.9% vs. 93.9%, P=0.033, Fig. 1). On multivariate
analysis incorporating age, T stage and the presence of bcl-
2(-)/ER(-) phenotype, the bcl-2(-)/ER(-) phenotype was the
only adverse prognostic factor for loco-regional relapse-free
survival (P=0.018). When the use of chemotherapy and hor-
monal therapy were added in the model, the prognostic sig-
nificance of the bcl-2(-)/ER(-) phenotype became marginal
(P=0.064).
For the distant metastasis-free survival, age less than 40 yr,
T2 stage and p53 positivity (Fig. 2) were adverse prognostic
factors (Table 2). Patients with bcl-2(-)/ER(-) phenotype had
an inferior distant metastasis-free survival rate than those with
other phenotypes, but the difference was not statistically sig-
nificant (77.9% vs. 93.0%, P=0.153). On multivariate anal-
236 K. Kim, E.K. Chie, W. Han, et al.
No. of patients No. of patients
Variables
P
value
P
value p53
(-)
p53
(+)
bcl-2
(+)
bcl-2
(-)
Age
<40 yr 7 15 0.741* 17 5 0.765*
≥40 yr 22 56 63 15
Tumor size
≤2 cm 19 51 0.531* 54 16 0.275
�
>2 cm 10 20 26 4
Nodal involvement
Negative 17 58 0.015* 58 17 0.248
�
Positive 12 13 22 3
Estrogen receptor
Negative 12 13 0.015*1 1 1 4 < 0.001*
Positive 17 58 69 6
Progesterone receptor
Negative 19 37 0.220* 38 18 <0.001
�
Positive 10 34 42 2
c-erbB2
Negative 20 55 0.373* 62 13 0.248*
Positive 9 16 18 7
Triple negative
Yes 10 9 0.011*8 1 1 < 0.001
�
No 19 62 72 9
bcl-2
Negative 11 9 0.004*- --
Positive 18 62
Table 1. Clinicopathologic variables according to the expression
of p53 and bcl-2
*chi-square test; 
� Fisher’s exact test.ysis incorporating aforementioned variables as well as nodal
and ER status, which were correlated with p53 expression,
only p53 expression was significant (P=0.009). The statisti-
cal significance of p53 expression remained even after the use
of chemotherapy and hormonal therapy were added in the
model (P=0.011).
In subgroup analysis with triple-negative phenotype (n=
19), bcl-2(-)/ER(-) phenotype was not associated with loco-
regional relapse (P=0.204), and p53 expression was not asso-
ciated with distant metastasis (P=0.331).
DISCUSSION
There have been several reports that investigated the prog-
nostic value of p53 or bcl-2 expression on loco-regional fail-
ure after breast conservative therapy. Elkhuizen et al. com-
pared 66 patients who experienced local recurrence with 139
matched controls in terms of the expression of several onco-
genes along with histological factors. They found that bcl-2
negativity carried a 17 times higher risk of local recurrence
in patients >50 yr (10). Noguchi et al. (9) and Turner et al.
(15) conducted similar case-control studies and noted the
association between local recurrence and p53 positivity. How-
ever, a case-control approach has the limitation of inevitable
biases in selecting control cases although the process is ran-
dom. In contrast, other studies which analyzed consecutive
patients failed to show any prognostic significance of these
markers on local control (8, 11, 16). This might be partly
due to the small number of events, that is, local recurrences
in early stage breast cancer patients receiving breast conser-
vative therapy.
We also failed to show that any of the two molecular mar-
kers was associated with loco-regional relapse-free survival.
Instead, the combined variable of bcl-2(-)/ER(-) phenotype
was proven to be a significant prognostic factor in univariate
and multivariate analyses. Given the association between bcl-
2 expression and ER status in a number of studies including
ours (11, 17-19), a combined analysis of bcl-2 and ER has
already been tried. Callagy et al. showed that the risk of death
in bcl-2(-)/ER(-) phenotype is higher than those in other three
phenotypes (20). Gasparini et al. demonstrated that the bcl-
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P value P value
Variables
5-yr
LRRFS
5-yr
DMFS Multi Uni Uni Multi
Age
<40 yr 80.6% 0.032 0.081 77.3% 0.033 0.123
≥40 yr 94.7% 94.8%
Tumor size
≤2 cm 95.7% 0.046 0.068 97.1% 0.002 0.061
>2 cm 82.6% 76.7%
Nodal involvement
Negative 94.7% 0.110 - 94.6% 0.076 0.452
Positive 82.8% 80.0%
Estrogen receptor
Negative 93.0% 0.347 - 93.3% 0.323 0.852
Positive 87.6% 83.4%
Progesterone receptor
Negative 92.8% 0.650 - 95.5% 0.498 -
Positive 90.7% 87.2%
p53
Negative 94.2% 0.181 - 97.1% <0.001 0.009
Positive 86.2% 75.9%
bcl-2
Negative 84.0% 0.140 - 78.7% 0.099 -
Positive 93.5% 93.8%
c-erbB2
Negative 90.3% 0.423 - 91.9% 0.359 -
Positive 96.0% 88.0%
Bcl-2(-)/ER(-)
Yes 77.9% 0.033 0.018 77.9% 0.153 -
No 93.9% 93.0%
Triple negative
Yes 89.2% 0.620 - 78.6% 0.107 -
No 92.3% 93.8%
Table 2. Univariate and multivariate analysis for 5-yr loco-regional
relapse-free and distant metastasis-free survival rate
LRRFS, loco-regional relapse-free survival; DMFS, distant metastasis-
free survival; ER, estrogen receptor.
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Fig. 1. Loco-regional relapse-free survival curves according to the
expression of bcl-2(-)/ER(-) phenotype.
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Fig. 2. Distant metastasis-free survival curves according to the ex-
pression of p53.2(-)/ER(-) phenotype had a 5.7 times higher risk of overall
recurrence compared with bcl-2(+)/ER(-) phenotype on mul-
tivariate analysis (12). Likewise, an analysis of several molec-
ular markers in combination provides more accurate prog-
nostic information than that of the single variable, even in
the low-risk group like our population.
For the distant metastasis, there are some limited data on
the prognostic value of these markers in the breast conserva-
tive treatment setting. Aforementioned case-control studies
noted a higher risk of distant metastases in patients with p53
expression (9, 15). Again, however, consecutive population-
based studies failed to verify the relationship, despite the lar-
ger number of patients and events (11, 17). In the current
study, p53 positivity was an independent prognostic factor
predicting distant metastasis-free survival after adjusting con-
ventional clinicopathologic variables including nodal and ER
status and treatment-related factors such as the use of chemo-
therapy and/or hormonal therapy.
Recently, a number of investigators are seeking for new
therapeutic strategy for triple-negative breast cancer, which
is associated with inferior distant metastasis-free survival (21-
23). Unlike other reports, however, triple negativity was not
a significant risk factor for distant metastasis in the present
study. However, the correlation between p53 expression and
triple-negative phenotype was demonstrated. This finding
was also observed by other studies (24, 25). Although the
prognostic impact of p53 expression in triple-negative tumors
was not established in our study as well as others (25), p53
expression can give therapeutic implication for those patients
with triple-negative tumors. Regarding this issue, Bidard et
al. showed that the rate of pathologic complete remission
was higher in patients with p53-positive tumors than those
with p53-negative tumors after neoadjuvant chemotherapy
for triple-negative breast cancer (26).
Despite the small number of patients and events, our study
demonstrated the prognostic significance of bcl-2 and p53
expression on loco-regional control and distant metastasis,
respectively. This is partly because our population is relative-
ly homogeneous, consisted of early stage breast cancer pati-
ents treated with breast conserving surgery and radiotherapy.
Moreover, accrual period of the patient was relatively short,
and therefore our patients were treated in a relatively uni-
form fashion regarding loco-regional therapy. But, the deliv-
ery of systemic therapy was somewhat various as decision to
undergo systemic therapy was based on the risk of the indi-
vidual patient and the subsequent gain with systemic thera-
py. Further studies with larger population are needed to con-
firm the results from this study. 
Unlike hormonal receptor expression or c-erbB2 expres-
sion, there is currently no specific treatment available to tar-
get tumors with either p53 expression or bcl-2 negativity.
But, breast cancer patients may be stratified into more detail-
ed subtypes by these markers as well as other more relevant
molecular markers, which are in the process of development.
Although more diversified patient and tumor specific treat-
ment strategies need to be elucidated from future trials, this
approach will eventually benefit patients undergoing treat-
ment for breast cancer.
In conclusion, results from this study show that a bcl-2(-)/
ER(-) phenotype and p53 positivity are useful molecular mar-
kers predicting loco-regional relapse-free and distant metas-
tasis-free survival, respectively, in patients treated with breast
conserving surgery and radiotherapy.
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